LONDON, Feb 10 (Reuters) - Some lymphoma patients who keep taking Genentech Inc and Biogen Idec's Rituxan after chemotherapy live 40 percent longer than those who stop taking the drug, Israeli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results